Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies

被引:44
|
作者
Costes, Safia [1 ]
Bertrand, Gyslaine [1 ]
Ravier, Magalie A. [1 ]
机构
[1] Univ Montpellier, CNRS, IGF, INSERM, F-34094 Montpellier, France
关键词
pancreatic beta-cells; islets; apoptosis; islet amyloid; lipotoxicity; glucotoxicity; GLP-1; ENDOPLASMIC-RETICULUM STRESS; GLUCAGON-LIKE PEPTIDE-1; ISLET-AMYLOID-POLYPEPTIDE; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; GLP-1 RECEPTOR AGONISTS; UBIQUITIN-PROTEASOME PATHWAY; INDUCED OXIDATIVE STRESS; SATURATED FATTY-ACIDS; INSULIN-SECRETION; PANCREATIC-ISLETS;
D O I
10.3390/ijms22105303
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Type 2 diabetes (T2D) is characterized by chronic hyperglycemia secondary to the decline of functional beta-cells and is usually accompanied by a reduced sensitivity to insulin. Whereas altered beta-cell function plays a key role in T2D onset, a decreased beta-cell mass was also reported to contribute to the pathophysiology of this metabolic disease. The decreased beta-cell mass in T2D is, at least in part, attributed to beta-cell apoptosis that is triggered by diabetogenic situations such as amyloid deposits, lipotoxicity and glucotoxicity. In this review, we discussed the molecular mechanisms involved in pancreatic beta-cell apoptosis under such diabetes-prone situations. Finally, we considered the molecular signaling pathways recruited by glucagon-like peptide-1-based therapies to potentially protect beta-cells from death under diabetogenic situations.
引用
收藏
页数:23
相关论文
共 27 条
  • [1] Research progress on the mechanism of beta-cell apoptosis in type 2 diabetes mellitus
    You, SuFang
    Zheng, JingYi
    Chen, YuPing
    Huang, HuiBin
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [2] Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta-cell protection in type 1 diabetes
    de Brachene, Alexandra Coomans
    Castela, Angela
    de Beeck, Anne Op
    Mirmira, Raghavendra G.
    Marselli, Lorella
    Marchetti, Piero
    Masse, Craig
    Miao, Wenyan
    Leit, Silvana
    Evans-Molina, Carmella
    Eizirik, Decio L.
    DIABETES OBESITY & METABOLISM, 2020, 22 (10) : 1827 - 1836
  • [3] Mediators and mechanisms of pancreatic beta-cell death in type 1 diabetes
    Pirot, Pierre
    Cardozo, Alessandra K.
    Eizirik, Decio L.
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2008, 52 (02) : 156 - 165
  • [4] Type 1 Diabetes Candidate Genes Linked to Pancreatic Islet Cell Inflammation and Beta-Cell Apoptosis
    Storling, Joachim
    Pociot, Flemming
    GENES, 2017, 8 (02):
  • [5] GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice
    Schwenk, Robert W.
    Baumeier, Christian
    Finan, Brian
    Kluth, Oliver
    Brauer, Christine
    Joost, Hans-Georg
    DiMarchi, Richard D.
    Tschoep, Matthias H.
    Schuermann, Annette
    DIABETOLOGIA, 2015, 58 (03) : 604 - 614
  • [6] Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications
    Wysham, Carol
    Shubrook, Jay
    POSTGRADUATE MEDICINE, 2020, 132 (08) : 676 - 686
  • [7] Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes
    Ajmal, Nida
    Bogart, Maislin C.
    Khan, Palwasha
    Max-Harry, Ibiagbani M.
    Nunemaker, Craig S.
    CELLS, 2023, 12 (11)
  • [8] GLP-1–oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice
    Robert W. Schwenk
    Christian Baumeier
    Brian Finan
    Oliver Kluth
    Christine Brauer
    Hans-Georg Joost
    Richard D. DiMarchi
    Matthias H. Tschöp
    Annette Schürmann
    Diabetologia, 2015, 58 : 604 - 614
  • [9] The central role of calcium in the effects of cytokines on beta-cell function: Implications for type 1 and type 2 diabetes
    Ramadan, James W.
    Steiner, Stephen R.
    O'Neill, Christina M.
    Nunemaker, Craig S.
    CELL CALCIUM, 2011, 50 (06) : 481 - 490
  • [10] Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies
    Penfornis, A.
    Borot, S.
    Raccah, D.
    DIABETES & METABOLISM, 2008, 34 : S78 - S90